Skip to main content

Advertisement

SpringerLink
Log in

The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review

  • Review
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Selinexor is a novel XPO1 inhibitor which inhibits the export of tumor suppressor proteins and oncoprotein mRNAs, leading to cell-cycle arrest and apoptosis in cancer cells. While selinexor is currently FDA approved to treat multiple myeloma, compelling preclinical and early clinical studies reveal selinexor’s efficacy in treating hematologic and non-hematologic malignancies, including sarcoma, gastric, bladder, prostate, breast, ovarian, skin, lung, and brain cancers. Current reviews of selinexor primarily highlight its use in hematologic malignancies; however, this review seeks to summarize the recent evidence of selinexor treatment in solid tumors.

Methods

Pertinent literature searches in PubMed and the Karyopharm Therapeutics website for selinexor and non-hematologic malignancies preclinical and clinical trials.

Results

This review provides evidence that selinexor is a promising agent used alone or in combination with other anticancer medications in non-hematologic malignancies.

Conclusion

Further clinical investigation of selinexor treatment for solid malignancies is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Availability of data and materials

All data generated or analyzed during this study are included in the published article.

References

  • Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF, Unger TJ, Saint-Martin JR, Carlson R, Landesman Y, McCauley D, Rashal T, Lassen U, Kim R, Stayner LA, Mirza MR, Kauffman M, Shacham S, Mahipal A (2016) First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol 34(34):4142–4150. https://doi.org/10.1200/jco.2015.65.3949

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Aboukameel A, Muqbil I, Baloglu E, Senapedis W, Landesman Y, Argueta C, Kauffman M, Chang H, Kashyap T, Shacham S, Neggers JE, Daelemans D, Heath EI, Azmi AS (2018) Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression. Oncotarget. https://doi.org/10.18632/oncotarget.26239

    Article  PubMed  PubMed Central  Google Scholar 

  • Aladhraei M, Kassem Al-Thobhani A, Poungvarin N, Suwannalert P (2019) Association of XPO1 Overexpression with NF-κB and Ki67 in colorectal cancer. Asian Pac J Cancer Prev 20(12):3747–3754. https://doi.org/10.31557/apjcp.2019.20.12.3747

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Alzahrani A, Natarajan U, Rathinavelu A (2022) Enhancement of MDM2 inhibitory effects through blocking nuclear export mechanisms in ovarian cancer cells. Cancer Genet 266–267:57–68. https://doi.org/10.1016/j.cancergen.2022.06.003

    Article  CAS  PubMed  Google Scholar 

  • Arango NP, Yuca E, Zhao M, Evans KW, Scott S, Kim C, Gonzalez-Angulo AM, Janku F, Ueno NT, Tripathy D, Akcakanat A, Naing A, Meric-Bernstam F (2017) Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Res 19(1):93. https://doi.org/10.1186/s13058-017-0878-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Attiyeh EF, Maris JM, Lock R, Reynolds CP, Kang MH, Carol H, Gorlick R, Kolb EA, Keir ST, Wu J, Landesman Y, Shacham S, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA (2016) Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): a report from the pediatric preclinical testing program. Pediatr Blood Cancer 63(2):276–286. https://doi.org/10.1002/pbc.25727

    Article  CAS  PubMed  Google Scholar 

  • Azmi AS, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman MG, Philip PA, Mohammad RM (2017) Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. Oncotarget 8(47):82144–82155. https://doi.org/10.18632/oncotarget.19285

    Article  PubMed  PubMed Central  Google Scholar 

  • Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M, Al-Hallak MN, Tesfaye A, Kim S, Shidham V, Mohammad MR, Philip PA (2020) Preclinical assessment with clinical validation of selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma. Clin Cancer Res 26(6):1338–1348. https://doi.org/10.1158/1078-0432.ccr-19-1728

    Article  CAS  PubMed  Google Scholar 

  • Baek HB, Lombard AP, Libertini SJ, Fernandez-Rubio A, Vinall R, Gandour-Edwards R, Nakagawa R, Vidallo K, Nishida K, Siddiqui S, Wettersten H, Landesman Y, Weiss RH, Ghosh PM, Mudryj M (2018) XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies. Oncotarget 9(77):34567–34581. https://doi.org/10.18632/oncotarget.26179

    Article  PubMed  PubMed Central  Google Scholar 

  • Bartley BR, Simonette RA, Rady PL, Doan HQ, Tyring SK (2022) Molecular evidence for selinexor as a treatment for Merkel cell polyomavirus (MCPyV)-positive Merkel cell carcinoma. Int J Dermatol. https://doi.org/10.1111/ijd.16057

    Article  PubMed  Google Scholar 

  • Chen CI, Gutierrez M, de Nully Brown P, Gabrail N, Baz R, Reece DE, Savona M, Trudel S, Siegel DS, Mau-Sorensen M, Kuruvilla J, Byrd JC, Shacham S, Rashal T, Yau CYF, McCauley D, Saint-Martin J-R, McCartney J, Landesman Y, Klebanov B, Pond G, Oza AM, Kauffman M, Mirza MR (2013) Anti tumor activity of selinexor (KPT-330), a first-in-class oral SELECTIVE inhibitor of nuclear export (SINE) XPO1/CRM1 antagonist In Patients (pts) with relapsed/refractory multiple myeloma (MM) Or Waldenstrom’s macroglobulinemia (WM). Blood 122(21):1942. https://doi.org/10.1182/blood.V122.21.1942.1942

    Article  Google Scholar 

  • Chen Y, Camacho SC, Silvers TR, Razak AR, Gabrail NY, Gerecitano JF, Kalir E, Pereira E, Evans BR, Ramus SJ, Huang F, Priedigkeit N, Rodriguez E, Donovan M, Khan F, Kalir T, Sebra R, Uzilov A, Chen R, Sinha R, Halpert R, Billaud JN, Shacham S, McCauley D, Landesman Y, Rashal T, Kauffman M, Mirza MR, Mau-Sørensen M, Dottino P, Martignetti JA (2017) Inhibition of the nuclear export receptor XPO1 as a therapeutic target for platinum-resistant ovarian cancer. Clin Cancer Res 23(6):1552–1563. https://doi.org/10.1158/1078-0432.Ccr-16-1333

    Article  CAS  PubMed  Google Scholar 

  • Conforti F, Wang Y, Rodriguez JA, Alberobello AT, Zhang Y-W, Giaccone G (2015) Molecular pathways: anticancer activity by inhibition of nucleocytoplasmic shuttling. Clin Cancer Res 21(20):4508–4513. https://doi.org/10.1158/1078-0432.Ccr-15-0408

    Article  CAS  PubMed  Google Scholar 

  • Conforti F, Zhang X, Rao G, De Pas T, Yonemori Y, Rodriguez JA, McCutcheon JN, Rahhal R, Alberobello AT, Wang Y, Zhang YW, Guha U, Giaccone G (2017) Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors. Cancer Res 77(20):5614–5627. https://doi.org/10.1158/0008-5472.Can-17-1323

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Corno C, Stucchi S, De Cesare M, Carenini N, Stamatakos S, Ciusani E, Minoli L, Scanziani E, Argueta C, Landesman Y, Zaffaroni N, Gatti L, Perego P (2018) FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models. Biochem Pharmacol 147:93–103. https://doi.org/10.1016/j.bcp.2017.11.009

    Article  CAS  PubMed  Google Scholar 

  • Crochiere ML, Kashyap T, Klebanov B, Senapedis W, Alamo DD, Tamir S, Baloglu E, McCauley D, Carlson R, Kauffman M, Shacham S, Demetri G, Wagner A, Sicinska E, Gokhale P, Kohl N, Saur A, Landesman Y (2014) Abstract 3810: Selinexor (KPT-330), a novel selective inhibitor of nuclear export (SINE), shows single agent efficacy against alveolar soft part sarcoma (ASPS) in vivo. Cancer Res 74(19):3810–3810. https://doi.org/10.1158/1538-7445.Am2014-3810

    Article  Google Scholar 

  • Culjkovic-Kraljacic B, Baguet A, Volpon L, Amri A, Borden KL (2012) The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation. Cell Rep 2(2):207–215. https://doi.org/10.1016/j.celrep.2012.07.007

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • De Cesare M, Cominetti D, Doldi V, Lopergolo A, Deraco M, Gandellini P, Friedlander S, Landesman Y, Kauffman MG, Shacham S, Pennati M, Zaffaroni N (2015) Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. Oncotarget 6(15):13119–13132. https://doi.org/10.18632/oncotarget.3761

    Article  PubMed  PubMed Central  Google Scholar 

  • DeSisto JA, Flannery P, Lemma R, Pathak A, Mestnik S, Philips N, Bales NJ, Kashyap T, Moroze E, Venkataraman S, Kung AL, Carter BD, Landesman Y, Vibhakar R, Green AL (2020) Exportin 1 inhibition induces nerve growth factor receptor expression to inhibit the NF-κB pathway in preclinical models of pediatric high-grade glioma. Mol Cancer Ther 19(2):540–551. https://doi.org/10.1158/1535-7163.Mct-18-1319

    Article  CAS  PubMed  Google Scholar 

  • Dev R, Zhong LL, Zarifa A, Albittar AA, Rubin L, Liu S, Yap TA, Dalal S, Hui D, Karp DD, Tsimberidou AM, Piha-Paul SA, Ahnert JR, Fu S, Meric-Bernstam F, Naing A (2022) Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. Invest New Drugs 40(1):124–133. https://doi.org/10.1007/s10637-021-01184-5

    Article  CAS  PubMed  Google Scholar 

  • Farren MR, Hennessey RC, Shakya R, Elnaggar O, Young G, Kendra K, Landesman Y, Elloul S, Crochiere M, Klebanov B, Kashyap T, Burd CE, Lesinski GB (2017) The exportin-1 inhibitor selinexor exerts superior antitumor activity when combined with T-cell checkpoint inhibitors. Mol Cancer Ther 16(3):417–427. https://doi.org/10.1158/1535-7163.Mct-16-0498

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • FDA. (2020). “FDA approves selinexor for refractory or relapsed multiple myeloma”. Retrieved 1 June 2022, from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-refractory-or-relapsed-multiple-myeloma

  • Ferreiro-Neira I, Torres NE, Liesenfeld LF, Chan CH, Penson T, Landesman Y, Senapedis W, Shacham S, Hong TS, Cusack JC (2016) XPO1 inhibition enhances radiation response in preclinical models of rectal cancer. Clin Cancer Res 22(7):1663–1673. https://doi.org/10.1158/1078-0432.Ccr-15-0978

    Article  CAS  PubMed  Google Scholar 

  • Fung HY, Chook YM (2014) Atomic basis of CRM1-cargo recognition, release and inhibition. Semin Cancer Biol 27:52–61. https://doi.org/10.1016/j.semcancer.2014.03.002

    Article  CAS  PubMed  Google Scholar 

  • Galinski B, Luxemburg M, Landesman Y, Pawel B, Johnson KJ, Master SR, Freeman KW, Loeb DM, Hébert JM, Weiser DA (2021) XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB. Transl Oncol 14(8):101114. https://doi.org/10.1016/j.tranon.2021.101114

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Garg M, Kanojia D, Mayakonda A, Said JW, Doan NB, Chien W, Ganesan TS, Huey Chuang LS, Venkatachalam N, Baloglu E, Shacham S, Kauffman M, Phillip Koeffler H (2016) Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma. Oncotarget. https://doi.org/10.18632/oncotarget.13485

    Article  PubMed  PubMed Central  Google Scholar 

  • Garg M, Kanojia D, Mayakonda A, Ganesan TS, Sadhanandhan B, Suresh S, Nagare SSRP, Said JW, Doan NB, Ding LW, Baloglu E, Shacham S, Kauffman M, Koeffler HP (2017) Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. Sci Rep 7(1):9749. https://doi.org/10.1038/s41598-017-10325-x

    Article  PubMed  PubMed Central  Google Scholar 

  • Gavriatopoulou M, Chari A, Chen C, Bahlis N, Vogl DT, Jakubowiak A, Dingli D, Cornell RF, Hofmeister CC, Siegel D, Berdeja JG, Reece D, White D, Lentzsch S, Gasparetto C, Huff CA, Jagannath S, Baz R, Nooka AK, Richter J, Abonour R, Parker TL, Yee AJ, Moreau P, Lonial S, Tuchman S, Weisel KC, Mohty M, Choquet S, Unger TJ, Li K, Chai Y, Li L, Shah J, Shacham S, Kauffman MG, Dimopoulos MA (2020) Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia 34(9):2430–2440. https://doi.org/10.1038/s41375-020-0756-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Golan T, ShentzerKutiel T, Geva R, Gottfried M, Zick A, Dudnik J, Netiv E, Zhang Y, Yang F, Sharoni S, Duic JP, Meng C, Michel D, Shah JJ, Kauffman MG, Shacham S, Zer A (2021) Open-label phase 1 study evaluating the tolerability and anti-tumor activity of selinexor and pembrolizumab in colorectal cancer. J Clin Oncol 39(15):e15579–e15579. https://doi.org/10.1200/JCO.2021.39.15_suppl.e15579

    Article  Google Scholar 

  • Gounder MM, Zer A, Tap WD, Salah S, Dickson MA, Gupta AA, Keohan ML, Loong HH, D’Angelo SP, Baker S, Condy M, Nyquist-Schultz K, Tanner L, Erinjeri JP, Jasmine FH, Friedlander S, Carlson R, Unger TJ, Saint-Martin JR, Rashal T, Ellis J, Kauffman M, Shacham S, Schwartz GK, Abdul Razak AR (2016) Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma. J Clin Oncol 34(26):3166–3174. https://doi.org/10.1200/jco.2016.67.6346

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno-Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gröschel S, Hatcher H, Duffaud F, Herráez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, Götze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben-Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S (2022) Selinexor in advanced, metastatic dedifferentiated liposarcoma: a multinational, randomized, double-blind, placebo-controlled trial. J Clin Oncol. https://doi.org/10.1200/jco.21.01829

    Article  PubMed  PubMed Central  Google Scholar 

  • Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C (2014a) Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol 7:85. https://doi.org/10.1186/s13045-014-0085-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gravina GL, Tortoreto M, Mancini A, Addis A, Di Cesare E, Lenzi A, Landesman Y, McCauley D, Kauffman M, Shacham S, Zaffaroni N, Festuccia C (2014b) XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa). J Hematol Oncol 7:46. https://doi.org/10.1186/1756-8722-7-46

    Article  PubMed  PubMed Central  Google Scholar 

  • Gravina GL, Mancini A, Sanita P, Vitale F, Marampon F, Ventura L, Landesman Y, McCauley D, Kauffman M, Shacham S, Festuccia C (2015) KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models. BMC Cancer 15:941–941. https://doi.org/10.1186/s12885-015-1936-z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gravina GL, Mancini A, Colapietro A, Marampon F, Sferra R, Pompili S, Biordi LA, Iorio R, Flati V, Argueta C, Landesman Y, Kauffman M, Shacham S, Festuccia C (2017) Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer. Oncotarget 8(67):111225–111245. https://doi.org/10.18632/oncotarget.22760

    Article  PubMed  PubMed Central  Google Scholar 

  • Green AL, Ramkissoon SH, McCauley D, Jones K, Perry JA, Hsu JH, Ramkissoon LA, Maire CL, Hubbell-Engler B, Knoff DS, Shacham S, Ligon KL, Kung AL (2015) Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma. Neuro Oncol 17(5):697–707. https://doi.org/10.1093/neuonc/nou303

    Article  CAS  PubMed  Google Scholar 

  • Gupta R, Simonette RA, Doan HQ, Rady PL, Tyring SK (2021) Targeting the expression of T antigens with selinexor (KPT-330) shows promise for Merkel cell polyomavirus-positive Merkel cell carcinoma treatment. Br J Dermatol 184(6):1185–1187. https://doi.org/10.1111/bjd.19801

    Article  CAS  PubMed  Google Scholar 

  • Handley KF, Rodriguez-Aguayo C, Ma S, Stur E, Joseph R, Bayraktar E, Dasari SK, Nguyen N, Powell RT, Sobieski M, Ivan C, Kim M, Umamaheswaran S, Glassman D, Wen Y, Amero P, Stephan C, Coleman RL, Landesman Y, Westin SN, Ram PT, Sood AK (2021) Rational combination of CRM1 inhibitor selinexor and olaparib shows synergy in ovarian cancer cell lines and mouse models. Mol Cancer Ther 20(12):2352–2361. https://doi.org/10.1158/1535-7163.Mct-21-0370

    Article  CAS  PubMed  Google Scholar 

  • Heong VYM, Koe P, Yong WP, Soo R, Chee CE, Wong A, Thian YL, Sundar R, Ho JS, Gopinathan A, Lee SC, Goh BC, Tan D (2016) RAS/AKT pathway mutations as predictive biomarkers in patients with colorectal cancer treated with the exportin 1 (XPO1) inhibitor selinexor (SEL); inhibition of nuclear-cytoplasmic translocation of p27 as a mechanism of anti-tumour activity. Ann Oncol 27:vil22. https://doi.org/10.1093/annonc/mdw368.26

    Article  Google Scholar 

  • Heong VYM, Goh ML, Yong WP, Soo RA, Chee CE, Raghav S, Goh BC, Lee SC, Lim J, Wong A, Tan DSP (2018) Phase Ib study of safety and tolerability of selinexor in Asian patients with advanced solid cancers. Annal Oncol 29:141. https://doi.org/10.1093/annonc/mdy279.418

    Article  Google Scholar 

  • Hong AL, Tseng YY, Cowley GS, Jonas O, Cheah JH, Kynnap BD, Doshi MB, Oh C, Meyer SC, Church AJ, Gill S, Bielski CM, Keskula P, Imamovic A, Howell S, Kryukov GV, Clemons PA, Tsherniak A, Vazquez F, Crompton BD, Shamji AF, Rodriguez-Galindo C, Janeway KA, Roberts CW, Stegmaier K, van Hummelen P, Cima MJ, Langer RS, Garraway LA, Schreiber SL, Root DE, Hahn WC, Boehm JS (2016) Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun 7:11987. https://doi.org/10.1038/ncomms11987

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jardin F, Pujals A, Pelletier L, Bohers E, Camus V, Mareschal S, Dubois S, Sola B, Ochmann M, Lemonnier F, Viailly PJ, Bertrand P, Maingonnat C, Traverse-Glehen A, Gaulard P, Damotte D, Delarue R, Haioun C, Argueta C, Landesman Y, Salles G, Jais JP, Figeac M, Copie-Bergman C, Molina TJ, Picquenot JM, Cornic M, Fest T, Milpied N, Lemasle E, Stamatoullas A, Moeller P, Dyer MJ, Sundstrom C, Bastard C, Tilly H, Leroy K (2016) Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. Am J Hematol 91(9):923–930. https://doi.org/10.1002/ajh.24451

    Article  CAS  PubMed  Google Scholar 

  • Jeitany M, Prabhu A, Dakle P, Pathak E, Madan V, Kanojia D, Mukundan V, Jiang YY, Landesman Y, Tam WL, Kappei D, Koeffler HP (2021) Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas. Cell Mol Life Sci 78(4):1837–1851. https://doi.org/10.1007/s00018-020-03620-w

    Article  CAS  PubMed  Google Scholar 

  • Kala J, Mamlouk O, Jhaveri KD (2020) Selinexor-associated hyponatremia: single-center, real-world data. Kidney Int 98(3):789–791. https://doi.org/10.1016/j.kint.2020.06.007

    Article  PubMed  Google Scholar 

  • Kashyap T, Argueta C, Aboukameel A, Unger TJ, Klebanov B, Mohammad RM, Muqbil I, Azmi AS, Drolen C, Senapedis W, Lee M, Kauffman M, Shacham S, Landesman Y (2016) Selinexor, a selective inhibitor of nuclear export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. Oncotarget 7(48):78883–78895. https://doi.org/10.18632/oncotarget.12428

    Article  PubMed  PubMed Central  Google Scholar 

  • Kau TR, Way JC, Silver PA (2004) Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 4(2):106–117. https://doi.org/10.1038/nrc1274

    Article  CAS  PubMed  Google Scholar 

  • Kazim S, Malafa MP, Coppola D, Husain K, Zibadi S, Kashyap T, Crochiere M, Landesman Y, Rashal T, Sullivan DM, Mahipal A (2015) Selective nuclear export inhibitor KPT-330 enhances the antitumor activity of gemcitabine in human pancreatic cancer. Mol Cancer Ther 14(7):1570–1581. https://doi.org/10.1158/1535-7163.Mct-15-0104

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kendra KL, Watson R, Lesinski GB (2017) Selinexor, a selective inhibitor of nuclear export (SINE), in patients with unresectable melanoma. J Clin Oncol 35(15):e21014–e21014. https://doi.org/10.1200/JCO.2017.35.15_suppl.e21014

    Article  Google Scholar 

  • Khan HY, Ge J, Nagasaka M, Aboukameel A, Mpilla G, Muqbil I, Szlaczky M, Chaker M, Baloglu E, Landesman Y, Mohammad RM, Azmi AS, Sukari A (2019) Targeting XPO1 and PAK4 in 8505C anaplastic thyroid cancer cells: putative implications for overcoming lenvatinib therapy resistance. Int J Mol Sci. https://doi.org/10.3390/ijms21010237

    Article  PubMed  PubMed Central  Google Scholar 

  • Khan HY, Nagasaka M, Li Y, Aboukameel A, Uddin MH, Sexton R, Bannoura S, Mzannar Y, Al-Hallak MN, Kim S, Beydoun R, Landesman Y, Mamdani H, Uprety D, Philip PA, Mohammad RM, Shields AF, Azmi AS (2022) Inhibitor of the nuclear transport protein XPO1 enhances the anticancer efficacy of KRAS G12C inhibitors in preclinical models of KRAS G12C-mutant cancers. Cancer Res Commun 2(5):342–352. https://doi.org/10.1158/2767-9764.crc-21-0176

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Krausert S, Brabetz S, Mack NL, Schmitt-Hoffner F, Schwalm B, Peterziel H, Mangang A, Holland-Letz T, Sieber L, Korshunov A, Oehme I, Jäger N, Witt O, Pfister SM, Kool M (2022) Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma. Neuro-Oncol Adv. https://doi.org/10.1093/noajnl/vdac026

    Article  Google Scholar 

  • Kulkoyluoglu-Cotul E, Smith BP, Wrobel K, Zhao YC, Chen KLA, Hieronymi K, Imir OB, Duong K, O’Callaghan C, Mehta A, Sahoo S, Haley B, Chang H, Landesman Y, Madak-Erdogan Z (2019) Combined targeting of estrogen receptor alpha and XPO1 prevent Akt activation remodel metabolic pathways and induce autophagy to overcome tamoxifen resistance. Cancers (Basel). https://doi.org/10.3390/cancers11040479

    Article  PubMed  Google Scholar 

  • Lassman AB, Wen PY, van den Bent MJ, Plotkin SR, Walenkamp AME, Green AL, Li K, Walker CJ, Chang H, Tamir S, Henegar L, Shen Y, Alvarez MJ, Califano A, Landesman Y, Kauffman MG, Shacham S, Mau-Sørensen M (2022) A Phase II study of the efficacy and safety of oral selinexor in recurrent glioblastoma. Clin Cancer Res 28(3):452–460. https://doi.org/10.1158/1078-0432.CCR-21-2225

    Article  CAS  PubMed  Google Scholar 

  • Lawrence Y, Shmueli E, Yarom N, Khaikin M, Venturero M, Apter S, Inbar Y, Aderka D, Halpern N, Berger R, Shani A, Schvimer M, Raskin S, Ackerstein A, Rashal T, Symon Z, Golan T (2018) Nuclear export inhibition for radiosensitization; a proof-of-concept phase I clinical trial of neoadjuvant KPT-330 plus chemoradiation in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 102(3):e10. https://doi.org/10.1016/j.ijrobp.2018.07.214

    Article  Google Scholar 

  • Lewin J, Malone E, Al-Ezzi E, Fasih S, Pedersen P, Accardi S, Gupta A, Abdul Razak A (2021) A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS). Eur J Cancer 144:360–367. https://doi.org/10.1016/j.ejca.2020.10.032

    Article  CAS  PubMed  Google Scholar 

  • Machlus KR, Wu SK, Vijey P, Soussou TS, Liu ZJ, Shacham E, Unger TJ, Kashyap T, Klebanov B, Sola-Visner M, Crochiere M, Italiano JE Jr, Landesman Y (2017) Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis. Blood 130(9):1132–1143. https://doi.org/10.1182/blood-2016-11-752840

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Marijon H, Gery S, Chang H, Landesman Y, Shacham S, Lee DH, de Gramont A, Koeffler HP (2021) Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status. Oncotarget 12(18):1749–1762. https://doi.org/10.18632/oncotarget.28047

    Article  PubMed  PubMed Central  Google Scholar 

  • Martini S, Figini M, Croce A, Frigerio B, Pennati M, Gianni AM, De Marco C, Daidone MG, Argueta C, Landesman Y, Zaffaroni N, Satta A (2020) Selinexor sensitizes TRAIL-R2-positive TNBC cells to the activity of TRAIL-R2xCD3 bispecific antibody. Cells. https://doi.org/10.3390/cells9102231

    Article  PubMed  PubMed Central  Google Scholar 

  • Mendonca J, Sharma A, Kim H-S, Hammers H, Meeker A, De Marzo A, Carducci M, Kauffman M, Shacham S, Kachhap S (2014) Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer. Oncotarget 5(15):6102–6112. https://doi.org/10.18632/oncotarget.2174

    Article  PubMed  PubMed Central  Google Scholar 

  • Moore SA, Narayanan D, Simonette RA, Bartley BR, Doan HQ, Rady PL, Tyring SK (2022) Selinexor is a novel inhibitor of DNA damage response in Merkel cell carcinoma. Clin Exp Dermatol. https://doi.org/10.1111/ced.15120

    Article  PubMed  Google Scholar 

  • Nair JS, Musi E, Schwartz GK (2017) Selinexor (KPT-330) induces tumor suppression through nuclear sequestration of IκB and downregulation of survivin. Clin Cancer Res 23(15):4301–4311. https://doi.org/10.1158/1078-0432.Ccr-16-2632

    Article  CAS  PubMed  Google Scholar 

  • Nakayama R, Zhang Y-X, Czaplinski JT, Anatone AJ, Sicinska ET, Fletcher JA, Demetri GD, Wagner AJ (2016) Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget. https://doi.org/10.18632/oncotarget.7667

    Article  PubMed  PubMed Central  Google Scholar 

  • Neggers JE, Vercruysse T, Jacquemyn M, Vanstreels E, Baloglu E, Shacham S, Crochiere M, Landesman Y, Daelemans D (2015) Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing. Chem Biol 22(1):107–116. https://doi.org/10.1016/j.chembiol.2014.11.015

    Article  CAS  PubMed  Google Scholar 

  • Nguyen R, Wang H, Sun M, Lee DG, Peng J, Thiele CJ (2022) Combining selinexor with alisertib to target the p53 pathway in neuroblastoma. Neoplasia 26:100776. https://doi.org/10.1016/j.neo.2022.100776

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nilsson S, Stein A, Rolfo C, Kranich AL, Mann J, Papadimitriou K, Theile S, Amberg S, Bokemeyer C (2020) Selinexor (KPT-330), an oral selective inhibitor of nuclear export (SINE) compound, in combination with FOLFOX in patients with metastatic colorectal cancer (mCRC)—final results of the phase I trial SENTINEL. Curr Cancer Drug Targets 20(10):811–817. https://doi.org/10.2174/1568009620666200628105727

    Article  CAS  PubMed  Google Scholar 

  • Pathak R, Zin F, Thomas C, Bens S, Gayden T, Karamchandani J, Dudley RW, Nemes K, Johann PD, Oyen F, Kordes U, Jabado N, Siebert R, Paulus W, Kool M, Frühwald MC, Albrecht S, Kalpana GV, Hasselblatt M (2021) Inhibition of nuclear export restores nuclear localization and residual tumor suppressor function of truncated SMARCB1/INI1 protein in a molecular subset of atypical teratoid/rhabdoid tumors. Acta Neuropathol 142(2):361–374. https://doi.org/10.1007/s00401-021-02328-w

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Podar K, Shah J, Chari A, Richardson PG, Jagannath S (2020) Selinexor for the treatment of multiple myeloma. Expert Opin Pharmacother 21(4):399–408. https://doi.org/10.1080/14656566.2019.1707184

    Article  PubMed  Google Scholar 

  • Quintanal-Villalonga A, Taniguchi H, Hao Y, Chow A, Zhan YA, Chavan SS, Uddin F, Allaj V, Manoj P, Shah NS, Chan JM, Offin M, Ciampricotti M, Ray-Kirton J, Egger J, Bhanot U, Linkov I, Asher M, Roehrl MH, Qiu J, de Stanchina E, Hollmann TJ, Koche RP, Sen T, Poirier JT, Rudin CM (2022) Inhibition of XPO1 sensitizes small cell lung cancer to first- and second-line chemotherapy. Cancer Res 82(3):472–483. https://doi.org/10.1158/0008-5472.Can-21-2964

    Article  CAS  PubMed  Google Scholar 

  • Richard S, Jagannath S (2022) Targeting nuclear export proteins in multiple myeloma therapy. BioDrugs 36(1):13–25. https://doi.org/10.1007/s40259-021-00514-6

    Article  CAS  PubMed  Google Scholar 

  • Riggi N, Knoechel B, Gillespie SM, Rheinbay E, Boulay G, Suvà ML, Rossetti NE, Boonseng WE, Oksuz O, Cook EB, Formey A, Patel A, Gymrek M, Thapar V, Deshpande V, Ting DT, Hornicek FJ, Nielsen GP, Stamenkovic I, Aryee MJ, Bernstein BE, Rivera MN (2014) EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell 26(5):668–681. https://doi.org/10.1016/j.ccell.2014.10.004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rosen JC, Weiss J, Pham NA, Li Q, Martins-Filho SN, Wang Y, Tsao MS, Moghal N (2021) Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts. Transl Oncol 14(10):101179. https://doi.org/10.1016/j.tranon.2021.101179

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rubinstein MM, Grisham RN, Cadoo K, Kyi C, Tew WP, Friedman CF, O’Cearbhaill RE, Zamarin D, Zhou Q, Iasonos A, Nikolovski I, Xu H, Soldan KN, Caird I, Martin M, Guillen J, Eid KT, Aghajanian C, Makker V (2021) A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers. Gynecol Oncol 160(1):71–76. https://doi.org/10.1016/j.ygyno.2020.10.019

    Article  CAS  PubMed  Google Scholar 

  • Saenz-Ponce N, Pillay R, de Long LM, Kashyap T, Argueta C, Landesman Y, Hazar-Rethinam M, Boros S, Panizza B, Jacquemyn M, Daelemans D, Gannon OM, Saunders NA (2018) Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aar7223

    Article  PubMed  Google Scholar 

  • Sexton R, Mahdi Z, Chaudhury R, Beydoun R, Aboukameel A, Khan HY, Baloglu E, Senapedis W, Landesman Y, Tesfaye A, Kim S, Philip PA, Azmi AS (2019) Targeting nuclear exporter protein XPO1/CRM1 in gastric cancer. Int J Mol Sci. https://doi.org/10.3390/ijms20194826

    Article  PubMed  PubMed Central  Google Scholar 

  • Seymour EK, Khan HY, Li Y, Chaker M, Muqbil I, Aboukameel A, Ramchandren R, Houde C, Sterbis G, Yang J, Bhutani D, Pregja S, Reichel K, Huddlestun A, Neveux C, Corona K, Landesman Y, Shah J, Kauffman M, Shacham S, Mohammad RM, Azmi AS, Zonder JA (2021) Selinexor in combination with R-CHOP for frontline treatment of non-hodgkin lymphoma: results of a phase I study. Clin Cancer Res 27(12):3307–3316. https://doi.org/10.1158/1078-0432.ccr-20-4929

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shafique M, Ismail-Khan R, Extermann M, Sullivan D, Goodridge D, Boulware D, Hogue D, Soliman H, Khong H, Han HS (2019) A phase II trial of selinexor (KPT-330) for metastatic triple-negative breast cancer. Oncologist 24(7):887-e416. https://doi.org/10.1634/theoncologist.2019-0231

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shang E, Zhang Y, Shu C, Ishida CT, Bianchetti E, Westhoff MA, Karpel-Massler G, Siegelin MD (2018) Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems. Sci Rep 8(1):15383. https://doi.org/10.1038/s41598-018-33784-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shi Y, Xu S, Li S (2022) Selinexor improves the anti-cancer effect of tucidinostat on TP53 wild-type breast cancer. Mol Cell Endocrinol 545:111558. https://doi.org/10.1016/j.mce.2022.111558

    Article  CAS  PubMed  Google Scholar 

  • Soung YH, Kashyap T, Nguyen T, Yadav G, Chang H, Landesman Y, Chung J (2017) Selective inhibitors of nuclear export (SINE) compounds block proliferation and migration of triple negative breast cancer cells by restoring expression of ARRDC3. Oncotarget 8(32):52935–52947. https://doi.org/10.18632/oncotarget.17987

    Article  PubMed  PubMed Central  Google Scholar 

  • Subhash VV, Yeo MS, Wang L, Tan SH, Wong FY, Thuya WL, Tan WL, Peethala PC, Soe MY, Tan DSP, Padmanabhan N, Baloglu E, Shacham S, Tan P, Koeffler HP, Yong WP (2018) Anti-tumor efficacy of selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor. Sci Rep 8(1):12248. https://doi.org/10.1038/s41598-018-30686-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sun H, Hattori N, Chien W, Sun Q, Sudo EL, Gl DL, Lim SL, Shacham S, Kauffman M, Nakamaki T, Koeffler HP (2014) KPT-330 has antitumour activity against non-small cell lung cancer. Br J Cancer 111(2):281–291. https://doi.org/10.1038/bjc.2014.260

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sun H, Lin DC, Cao Q, Guo X, Marijon H, Zhao Z, Gery S, Xu L, Yang H, Pang B, Lee VK, Lim HJ, Doan N, Said JW, Chu P, Mayakonda A, Thomas T, Forscher C, Baloglu E, Shacham S, Rajalingam R, Koeffler HP (2016) CRM1 inhibition promotes cytotoxicity in ewing sarcoma cells by repressing EWS-FLI1-dependent IGF-1 signaling. Cancer Res 76(9):2687–2697. https://doi.org/10.1158/0008-5472.Can-15-1572

    Article  CAS  PubMed  Google Scholar 

  • Tran EJ, King MC, Corbett AH (2014) Macromolecular transport between the nucleus and the cytoplasm: advances in mechanism and emerging links to disease. Biochim Biophys Acta 1843(11):2784–2795. https://doi.org/10.1016/j.bbamcr.2014.08.003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Zarifa A, Shah J, Milton DR, Bean S, McQuinn L, Gong J, Colen R, Carter BW, Subbiah V, Ogbonna DC, Pant S, Meric-Bernstam F, Naing A (2021) Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: results of an openlabel, single-center, multi-arm phase Ib study. Investigational New Drugs 39(5):1357–1365. https://doi.org/10.1007/s10637-021-01119-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tremblay G, Daniele P, Breeze J, Li L, Shah J, Shacham S, Kauffman M, Engelhardt M, Chari A, Nooka A, Vogl D, Gavriatopoulou M, Dimopoulos MA, Richardson P, Biran N, Siegel D, Vlummens P, Doyen C, Facon T, Mohty M, Meuleman N, Levy M, Costa L, Hoffman JE, Delforge M, Kaminetzky D, Weisel K, Raab M, Dingli D, Tuchman S, Laurent F, Vij R, Schiller G, Moreau P, Richter J, Schreder M, Podar K, Parker T, Cornell RF, Lionel K, Choquet S, Sundar J (2021) Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. BMC Cancer 21(1):993. https://doi.org/10.1186/s12885-021-08453-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vergote IB, Lund B, Peen U, Umajuridze Z, Mau-Sorensen M, Kranich A, Van Nieuwenhuysen E, Haslund C, Nottrup T, Han SN, Concin N, Unger TJ, Chai Y, Au N, Rashal T, Joshi A, Crochiere M, Landesman Y, Shah J, Shacham S, Kauffman M, Mirza MR (2020) Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies. Gynecol Oncol 156(2):308–314. https://doi.org/10.1016/j.ygyno.2019.11.012

    Article  CAS  PubMed  Google Scholar 

  • Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK (2018) Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol 36(9):859–866. https://doi.org/10.1200/jco.2017.75.5207

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • von Fallois M, Kosyna FK, Mandl M, Landesman Y, Dunst J, Depping R (2021) Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity. J Cancer Res Clin Oncol 147(7):2025–2033. https://doi.org/10.1007/s00432-021-03626-2

    Article  CAS  Google Scholar 

  • Wahba A, Rath BH, O’Neill JW, Camphausen K, Tofilon PJ (2018) The XPO1 inhibitor selinexor inhibits translation and enhances the radiosensitivity of glioblastoma cells grown in vitro and in vivo. Mol Cancer Ther 17(8):1717–1726. https://doi.org/10.1158/1535-7163.MCT-17-1303

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang J, Sun T, Meng Z, Wang L, Li M, Chen J, Qin T, Yu J, Zhang M, Bie Z, Dong Z, Jiang X, Lin L, Zhang C, Liu Z, Jiang R, Yang G, Li L, Zhang Y, Huang D (2021) XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a. Cancer Lett 503:197–212. https://doi.org/10.1016/j.canlet.2021.01.008

    Article  CAS  PubMed  Google Scholar 

  • Wei XX, Siegel AP, Aggarwal R, Lin AM, Friedlander TW, Fong L, Kim W, Louttit M, Chang E, Zhang L, Ryan CJ (2018) A phase II trial of selinexor, an oral selective inhibitor of nuclear export compound, in abiraterone- and/or enzalutamide-refractory metastatic castration-resistant prostate cancer. Oncologist 23(6):656-e664. https://doi.org/10.1634/theoncologist.2017-0624

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wettersten HI, Landesman Y, Friedlander S, Shacham S, Kauffman M, Weiss RH (2014) Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth. PLoS ONE 9(12):e113867. https://doi.org/10.1371/journal.pone.0113867

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wrobel K, Zhao YC, Kulkoyluoglu E, Chen KL, Hieronymi K, Holloway J, Li S, Ray T, Ray PS, Landesman Y, Lipka AE, Smith RL, Madak-Erdogan Z (2016) ERα-XPO1 cross talk controls tamoxifen sensitivity in tumors by altering ERK5 cellular localization. Mol Endocrinol 30(10):1029–1045. https://doi.org/10.1210/me.2016-1101

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wu T, Chen W, Zhong Y, Hou X, Fang S, Liu CY, Wang G, Yu T, Huang YY, Ouyang X, Li HQ, Cui L, Yang Y (2017) Nuclear export of ubiquitinated proteins determines the sensitivity of colorectal cancer to proteasome inhibitor. Mol Cancer Ther 16(4):717–728. https://doi.org/10.1158/1535-7163.MCT-16-0553

    Article  CAS  PubMed  Google Scholar 

  • Zheng Y, Gery S, Sun H, Shacham S, Kauffman M, Koeffler HP (2014) KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma. Cancer Chemother Pharmacol 74(3):487–495. https://doi.org/10.1007/s00280-014-2495-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhu Z-C, Liu J-W, Yang C, Zhao M, Xiong Z-Q (2019) XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis. Cell Death Dis 10(6):395. https://doi.org/10.1038/s41419-019-1627-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zuco V, Pasquali S, Tortoreto M, Brich S, Percio S, Dagrada GP, Colombo C, Sanfilippo R, Lauricella C, Gounder M, El Bezawy R, Barisella M, Dei Tos AP, Casali PG, Gronchi A, Stacchiotti S, Zaffaroni N (2021) Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation. J Exp Clin Cancer Res 40(1):83. https://doi.org/10.1186/s13046-021-01886-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This article has no funding source.

Author information

Authors and Affiliations

  1. Department of Dermatology, The University of Texas Health Science Center at Houston, 6431 Fannin St., MSB Room 1.308, Houston, TX, 77070, USA

    Jennifer R. Landes, Stephen A. Moore, Brooke R. Bartley, Hung Q. Doan, Peter L. Rady & Stephen K. Tyring

  2. Division of Internal Medicine, Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Hung Q. Doan

Authors
  1. Jennifer R. Landes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen A. Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brooke R. Bartley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hung Q. Doan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter L. Rady
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stephen K. Tyring
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed equally to the preparation of this review.

Corresponding author

Correspondence to Stephen K. Tyring.

Ethics declarations

Conflict of interest

Jennifer R. Landes, Stephen A. Moore, Brooke R. Bartley, Hung Q. Doan, Peter L. Rady, and Stephen K. Tyring declare that they have no relevant financial or non-financial interests to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Landes, J.R., Moore, S.A., Bartley, B.R. et al. The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review. J Cancer Res Clin Oncol 149, 2139–2155 (2023). https://doi.org/10.1007/s00432-022-04247-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-022-04247-z

Keywords

Search

Navigation